SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Windlas Biotech Ltd

BSE: 543329 NSE: WINDLAS ISIN: INE0H5O01029
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Windlas Biotech Ltd belong to?
Windlas Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Windlas Biotech Ltd a good quality company?
Windlas Biotech Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Windlas Biotech Ltd undervalued or overvalued?
Windlas Biotech Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Windlas Biotech Ltd a good buy now?
Windlas Biotech Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Windlas Biotech Ltd?
Windlas Biotech Ltd revenue growth is 20.4% for FY-2025 , which is above its 5 year CAGR of 18.2% , indicating faster growth.
Q.2 Gross Profit margin of Windlas Biotech Ltd?
Windlas Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 14.1% for FY-2025 , which is above its 5 year median of 13.5% , indicating increasing margins.
Q.3 Operating Profit Margin of Windlas Biotech Ltd?
Windlas Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 12.39% for FY-2025 , which is above its 5 year median of 12.38% indicating increasing margins.
Q.4 Net Profit Margin of Windlas Biotech Ltd?
Windlas Biotech Ltd Net Profit Margin is 7.98% for FY-2025 , is below with its 5 year median of 8.28%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 14.1 13.5
Operating Profit Margin 12.39 12.38
Net Profit Margin 7.98 8.28
Q.5 Return on Asset of Windlas Biotech Ltd?
Windlas Biotech Ltd Return on Asset is 8.75%, which is in line with its 5 year historical median of 8.75%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Windlas Biotech Ltd?
Windlas Biotech Ltd Return on equity is 12.82% for FY-2025 , which is in line with its historical median of 12.82%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Windlas Biotech Ltd?
Windlas Biotech Ltd Return on capital employed is 17.04% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Windlas Biotech Ltd?
Windlas Biotech Ltd Cash conversion cycle is 30 days, below its historical median of 41 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.1 1.1
ROE 12.82 12.82
ROCE 17.04 15.03
Cash Conversion Cycle 30 days 41 days
Q.9 Debt to Equity ratio of Windlas Biotech Ltd?
Windlas Biotech Ltd Debt-to-Equity ratio is 0.05 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Windlas Biotech Ltd?
Windlas Biotech Ltd Debt to cash flow from operations is 0.4 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Windlas Biotech Ltd?
Promoters hold 61.90% of the Windlas Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Windlas Biotech Ltd vs industry peers?
Windlas Biotech Ltd revenue CAGR is 18.24% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 759.9 137.1
Gross Profit 107.2 15.1
Operating Profit 94 16
Net Profit 61 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.1 0.8
ROE 12.82 8.91
ROCE 17.04 11.59
Cash Conversion Cycle (days) 29.75 76

Valuation & price assessment

Q.1 Stock return of Windlas Biotech Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 51.16% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - 51.2% -20.2%
Q.3 Valuation ratios of Windlas Biotech Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 27.58 16.78 40.28
Price to Book 3.35 1.85 2.77
Price to Sales 2.12 1.40 2.65
EV to EBITDA 15 9.94 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×